Embecta saw the highest growth of 299% in patent filings in November and 99% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 99% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Embecta’s patent filings and grants. Buy the databook here.
Embecta has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly . The World Intellectual Property Organization(WIPO), United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where Embecta is filings its patents. Among the top granted patent authorities, Embecta has 50% of its grants in European Patent Office(EPO) and 50% in United States(US).
Amgen and Sanofi could be the strongest competitors for Embecta
See Also:
In terms of grant share, Embecta stands in eighth position among its competitors. Amgen and Sanofi secured the top positions according to recent patent publication data.
Patents related to mobile and healthtech lead Embecta's portfolio
Embecta has the highest number of patents in mobile followed by, healthtech and connected care. For mobile, nearly 18% of patents were filed and no patents were granted in Q4 2023.
Drug delivery devices related patents lead Embecta portfolio followed by healthcare it, and other remote patient monitoring
Embecta has highest number of patents in drug delivery devices followed by healthcare it, other remote patient monitoring, glucose monitoring, and mobiles, hand-helds, pdas, smartphones.
For comprehensive analysis of Embecta's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.